Post-stroke depression

Primary Care & Stroke Prevention Clinic Update
March 20th, Donald Gordon Conference Centre, Kingston

Dr. Maria Hussain, MD FRCPC
Geriatric Psychiatrist
Assistant Professor
Department of Psychiatry
Queen’s University

Emily St. Denis, MD MSc
PGY4 Psychiatry Resident
Department of Psychiatry
Queen’s University
Faculty: Maria Hussain MD FRC PC
Emily St. Denis MD MSc

Relationships with commercial interests:

- Grants/Research Support: None
- Speakers Bureau/Honoraria: None
- Consulting Fees: None
- Other: None
At the end of this session the participant will be able to:

- Understand the prevalence and impact of Post Stroke Depression (PSD)
- Understand the utility of various screening tools for PSD
- Develop an approach to management of PSD, with a focus on outpatient management
Prevalence of PSD

• 62,000 people with stroke and TIA are treated in Canadian hospitals every year
• PSD: Most frequent psychiatric complication following stroke
• Pooled prevalence of depression at any time after stroke
  – In population studies 22%
  – In hospital studies 30%
  – In rehabilitation studies 30%
Risk factors for PSD

- Increased post stroke impairment
- History of depression predating stroke
- Cognitive impairment
- Anxiety
- Social Isolation
- Risk increases exponentially if more than one risk factor is present
- Associated lesions (inconsistent data):
  - Greatest risk with left frontal strokes and left basal ganglia lesions

- Depression itself is a risk factor for the occurrence of stroke with a prospective population based cohort study reflecting a RR=1.73

Ayerbe Stroke 2011
Morrison J Psychosom Res 2005
Caeiro J Psychiatry Neurosci 2006
Jonas Psychosomatic Medicine 2000
Allan BJPsych 2013
Why assess and treat?

![Bar chart showing the percentage of patients with major and minor depression in different settings.](image)

Robinson Am J Psychiatry 2016
Why assess and treat?

- Poorer functional recovery
- Increased risk for dependence
- Poorer cognitive function
- Reduced social participation
- Increased hospital visits, length of stay in hospital
- Increased depression in family and caregivers (30-60%)
- Suicidal ideation; suicidal death
- Increased mortality risk

Carota, A., Paolucci, S. The Behavioural and Cognitive Neurology of Stroke, Ch 29, 20
Screening of PSD

• All patients with stroke should be screened for depression using a validated tool (Evidence Levels A)
• Screening should take place at various stages throughout the continuum of stroke care [Evidence Level C]:
  – during acute care stay
  – following hospital discharge to an outpatient or community-based healthcare setting
  – throughout rehabilitation
  – periodically, following discharge to the community

Canadian Best Practice Recommendations for Stroke Care 2015
• Major depressive disorder:
  – 5 or more symptoms nearly every day for 2+ weeks:
  • One symptom must be: 1) **Depressed mood** or 2) **loss of interest**
    – Depressed mood most of the day
    – Markedly diminished interest or anhedonia
    – Significant weight loss (unintentional)
    – Insomnia (typical) or hypersomnia (atypical)
    – Psychomotor agitation or slowing
    – Fatigue
    – Feelings of worthlessness or excessive / inappropriate guilt
    – Diminished ability to think, concentrate, make decisions
    – Recurrent thoughts of death or suicidal ideation
• Depressive disorder due to another medical condition:
  – Prominent and persistent period of depressed mood or markedly diminished interest or pleasure in all, or almost all, activities
  • With depressive features, major depression-like episode, mixed

  – Onset can be acute or weeks to months after CVA
Patients with PSD more likely to have:

- Later age of onset
- Greater cognitive impairment
- Less family and personal history of depression
- Greater physical impairment

Patients with PSD and executive dysfunction have poor response to treatment with antidepressants and a more chronic and relapsing clinical course.

Robinson Am J Psychiatry 2016
Differential diagnosis

- Adjustment disorder
  - Number and quality of depressive symptoms will be less
- Post stroke apathy syndrome
  - Will not have mood component
- Post stroke emotional lability (pseudobulbar affect)
  - Can be mistaken for delirium, bipolar disorder
  - Will not have associated happiness or sadness
- Hypoactive delirium, dementia
Screening and assessment tools

• All patients with stroke should be screened for depression
• Screening complicated by aphasia, cognitive deficits, somatic stroke-related symptoms
• Clinical history, patient interview, mental status examination, collateral from caregivers

• Recommended first line screening tools:
  – Geriatric Depression Scale (GDS)
  – Hospital Anxiety and Depression Scale (HADS)
  – Patient Health Questionnaire – 9 (PHQ-9)

• Consider for aphasic patients:
  – Stroke Aphasic Depression Questionnaire – 10
  – Aphasia Depression Rating Scale

Canadian Best Practice Recommendations for Stroke Care 2015
## PSD Assessment

<table>
<thead>
<tr>
<th></th>
<th>PHQ-9</th>
<th>HADS</th>
<th>GDS</th>
<th>SADQ-10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rater</strong></td>
<td>Self-Rated or Interviewer Administered</td>
<td>Self-Rated or Interviewer Administered</td>
<td>Self-Rated or Interviewer Administered</td>
<td>Observer/Caregiver Rated</td>
</tr>
<tr>
<td><strong>Time in minutes</strong></td>
<td>2-4</td>
<td>2-5</td>
<td>8-10</td>
<td>2-4</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Adults, Older adults</td>
<td>Adults, Older adults</td>
<td>Developed in Older adults</td>
<td>Stroke Population</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>Free</td>
<td>$</td>
<td>Free</td>
<td>Free</td>
</tr>
<tr>
<td><strong>Misc</strong></td>
<td>Based DSM-IV</td>
<td>Both D + A</td>
<td>Possible use aphasia</td>
<td>Rater: Family vs. health professional</td>
</tr>
</tbody>
</table>
The Patient Health Questionnaire (PHQ-9)

<table>
<thead>
<tr>
<th>Patient Name</th>
<th>Date of Visit</th>
</tr>
</thead>
</table>

**Over the past 2 weeks, how often have you been bothered by any of the following problems?**

<table>
<thead>
<tr>
<th>Problem</th>
<th>Not At all</th>
<th>Several Days</th>
<th>More Than Half the Days</th>
<th>Nearly Every Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Little interest or pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2. Feeling down, depressed or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3. Trouble falling asleep, staying asleep, or sleeping too much</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4. Feeling tired or having little energy</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>5. Poor appetite or overeating</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>6. Feeling bad about yourself - or that you’re a failure or have let yourself or your family down</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>7. Trouble concentrating on things, such as reading the newspaper or watching television</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>8. Moving or speaking so slowly that other people could have noticed. Or, the opposite - being so fidgety or restless that you have been moving around a lot more than usual</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>9. Thoughts that you would be better off dead or of hurting yourself in some way</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

**Column Totals**

Add Totals Together

**Total Score Depression Severity**

0-4 None  
5-9 Mild depression  
10-14 Moderate depression  
15-19 Moderately severe depression  
20-27 Severe depression

10. If you checked off any problems, how difficult have those problems made it for you?

- [ ] Not difficult at all  
- [ ] Somewhat difficult  
- [ ] Very difficult  
- [ ] Extremely difficult
• First step approach
• Quick, simple to administer, showed promising results when evaluated in patients with non aphasic stroke
• Cut off score of 3 for depressive disorders
  • Positive screen should be further evaluated with a PHQ-9

### The Patient Health Questionnaire-2 (PHQ-2)

<table>
<thead>
<tr>
<th>Problem</th>
<th>Not At All</th>
<th>Several Days</th>
<th>More Than Half the Days</th>
<th>Nearly Every Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Little interest or pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2. Feeling down, depressed or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>
Please indicate how often in the last week the patient has shown the following behaviours:

<table>
<thead>
<tr>
<th>Question</th>
<th>Sometimes</th>
<th>Rarely</th>
<th>Never</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does he/she have weeping spells?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she have restless disturbed nights?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she avoid eye contact when you talk to him/her?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she burst into tears?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she complain of aches and pains?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she get angry?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she refuse to participate in social activities?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is he/she restless and fidgety?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she sit without doing anything?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does he/she keep him/herself occupied during the day?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SADQ-10**

- Scores range from 0-30
- Scores $\geq 15$ may represent presence of depression (Leeds et al., 2004)
• Non-pharmacological and Adjunct Treatments

• Pharmacotherapy
• Patients should be given information and advice about the impact of stroke, and the opportunity to talk about the impact on their lives [Evidence Level B].

• Patients and their caregivers should have their psychosocial and support needs reviewed on a regular basis as part of long-term stroke management [Evidence Level A].
Psychotherapy for PSD

• There is inadequate evidence at present to support the use of psychotherapy as monotherapy in the treatment of PSD [Evidence Level C].

• Reasonable to consider these therapies as one of the first line treatments for depressive disorders post-stroke, given demonstrated efficacy in primary depressive disorders (Evidence Level A).

• May be used as adjunctive therapies (Evidence Level B)
Psychotherapy for PSD

• Cochrane review: no evidence of effectiveness of psychotherapy to treat depression after stroke

• Since Cochrane review, some encouraging RCTs:
  • CALM study:
    – Behavior therapy in aphasic stroke patients offered for 3 months up to 20 sessions
    – maximizing mood-elevating activities
    – education, activity monitoring, activity scheduling, and graded task assignments
    – resulted in improvement in mood as compared to usual care

Hackett, Cochrane, 2008
Thomas, Clin Rehabil 2012
8-week adjunctive nurse-delivered brief psycho-social behavioral intervention in addition to antidepressant

- Stroke Recovery materials provided
- Medication diary
- Education around PSD in sessions
- Increased pleasant social and physical activity
- Individualized Problem Solving strategies

found to be effective as compared to antidepressant alone for remission of PSD at all time points (9wks, 6mths, 1yr)

Mitchell, Stroke, 2009
Patients diagnosed with a depressive disorder should be given a trial of antidepressant medication, if no contraindication exists. [Evidence Level A].

Treatment should be monitored; should continue for a minimum of six months if a good response is achieved [Evidence Level A].
Pharmacological Therapies

• Meta-analysis of antidepressants for post-stroke depression (10 studies)
  – 8 SSRIs, 2 TCAs, 1 trazodone
  – Recovery or remission of depression: OR: 2.58 (1.56 – 4.26, p=0.002)

• Cochrane
  – A small but significant effect of pharmacotherapy on treating depression and reducing depressive symptoms was found, as was a significant increase in adverse events.

• Recent meta-analysis replicated finding

Price, J Neurol Neurosurg Psychiatry, 2011
Hackett, Cochrane, 2008
Xu, Medicine, 2016
Pharmacotherapy

Robinson Am J Psychiatry 2016
Pharmacotherapy

• Both TCAs and SSRIs effective for PSD
• Relatively little comparative information on how to make the choice of one AD over another

• SNRIs:
  – Duloxetine vs. Citalopram and Sertraline
  – Duloxetine more effective in reducing symptoms of depression and anxiety

1. Paolucci, Neuropsychiatr Dis Treat. 2008
Antidepressants and Risk of Intracerebral Hemorrhage

- Antidepressants increase the risk of bleeding related adverse events:
  - Upper GI bleeds, perioperative bleeding
  - Mediated through anti-platelet aggregation effects of serotonergic antidepressants
- Risk of intracerebral hemorrhage with SSRIs:
  - RR: 1.42 (95% CI: 1.23 – 1.65)
  - RR: 1.5 for antidepressants combined with oral anticoagulants (above anticoagulants alone)
  - Absolute risk: 1/10,000 treated for 1 year

Hackam, Neurology, 2012
Antidepressants for Stroke Recovery

• Cochrane review of 52 RCTs\(^2\)
  – Reduced dependency, neurological deficits, depression
  – No benefit in cognitive status and death
  – Insufficient evidence to recommend routine use

• Routine use of prophylactic antidepressants is not recommended in post-stroke patients at this time [Evidence Level A]

Mead, Stroke, 2013
Antidepressants for Stroke Recovery

• RCT of fluoxetine (20 mg daily) vs. placebo for adults with acute ischemic stroke (5-10 days post stroke) treated for 3 months, all patients received physiotherapy
  – Excluded patients with depression
  – Fluoxetine group had significant improvement in motor recovery effect only observed at 90 days

• RCT of problem solving therapy vs. escitalopram in prevention of depression demonstrated cognitive benefit of escitalopram

Chollet, Lancet Neurology, 2011
Jorge, JAMA Psychiatry, 2010
• Antidepressants
  • No clear effect of pharmacological therapy on the prevention of depression in a Cochrane review

• AD prophylaxis was associated with a significant reduction in the occurrence rate of newly developed post stroke depression in another meta-analysis

• PST adapted for use in stroke population, 12 sessions, found to be effective

Hackett, Cochrane, 2008
Robinson, JAMA, 2008
Prevention of Post Stroke Depression

FIGURE 3. Randomized Controlled Trials for Evaluation of Preventative Treatments for Poststroke Depression

<table>
<thead>
<tr>
<th>Study</th>
<th>Escitalopram</th>
<th>Problem solving therapy</th>
<th>Sertraline</th>
<th>Fluoxetine</th>
<th>Mirtazapine</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robinson et al. (79) (52 weeks)</td>
<td>58</td>
<td>7</td>
<td>34</td>
<td>5</td>
<td>11</td>
<td>63</td>
</tr>
<tr>
<td>Rasmussen et al. (90) (52 weeks)</td>
<td>67</td>
<td>8</td>
<td>43</td>
<td>3</td>
<td>12</td>
<td>54</td>
</tr>
<tr>
<td>Almeida et al. (91) (24 weeks)</td>
<td>52</td>
<td>10</td>
<td>31</td>
<td>3</td>
<td>11</td>
<td>63</td>
</tr>
<tr>
<td>Chollet et al. (50) (12 weeks)</td>
<td>63</td>
<td>10</td>
<td>35</td>
<td>5</td>
<td>12</td>
<td>57</td>
</tr>
<tr>
<td>Tsai et al. (82) (52 weeks)</td>
<td>51</td>
<td>5</td>
<td>28</td>
<td>2</td>
<td>10</td>
<td>52</td>
</tr>
</tbody>
</table>

Completers
Robinson et al.: 134
Rasmussen et al.: 67
Almeida et al.: 56
Chollet et al.: 88
Tsai et al.: 55

Randomized
Robinson et al.: 176
Rasmussen et al.: 137
Almeida et al.: 92
Chollet et al.: 113
Tsai et al.: 111

Robinson Am J Psych 2016
Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression: A systematic review and meta-analysis of randomized controlled clinical trials

XinYi Shen\textsuperscript{a,1}, MingYi Liu\textsuperscript{a,1}, Yu Cheng\textsuperscript{a,1}, Cui Jia\textsuperscript{b,1}, XinYue Pan\textsuperscript{a}, QingYun Gou\textsuperscript{a}, XinLian Liu\textsuperscript{b}, Hui Cao\textsuperscript{b}, LuShun Zhang\textsuperscript{b,c,*}

\textsuperscript{a} Department of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China
\textsuperscript{b} Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu 610500, China
\textsuperscript{c} Development and Regeneration Key Laboratory of Sichuan Province, Department of Neurobiology, Chengdu Medical College, Chengdu 610500, China

\textbf{ARTICLE INFO}

\textbf{Keywords:}
Post-stroke depression
Transcranial magnetic stimulation
Meta-analysis

\textbf{ABSTRACT}

\textbf{Background:} Every year, more than fifteen million people worldwide experience a stroke, nearly 30% of stroke survivors are likely to experience post-stroke depression (PSD). Repetitive transcranial magnetic stimulation (rTMS) is one of the emerging techniques which assist in targeting rehabilitation after stroke. Although deterioration of PSD greatly affects the recovery and quality of life of stroke sufferers, the effect of rTMS therapy has not been systematically studied.

\textbf{Objective:} A systematic review and meta-analysis was conducted to determine the effect of rTMS on PSD.

\textbf{Methods:} We carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) of rTMS for the treatment of PSD. Primary outcome was severity of depression measured by the Hamilton Depression Rating Scale (HAMD). Secondary outcomes were response rates, remission rates, stroke severity and ability to perform daily activities.

\textbf{Results:} 22 RCTs studies (n=1764 patients) were included. The results demonstrated that rTMS was beneficial on PSD using three scales: HAMD (MD=−6.09, 95% CI: −7.74, −4.45, \textit{P} < 0.001); response rates (OR=3.46, 95% CI: 2.52, 4.76, \textit{P} < 0.00001); remission rates (OR 0.99, 95% CI: 0.56, 1.75, \textit{P} < 0.00001); National Institutes of Health Stroke Scale (NIHSS) (MD=−2.74, 95% CI: −3.33, −2.15, \textit{P} < 0.001); Activities of daily living (ADL) (SMD=−1.20, 95% CI: 0.68, 1.72, \textit{P} < 0.001); Montgomery-Asberg Depression Scale (MADRS) (MD=−6.21, 95% CI: −9.34, −3.08, \textit{P} =0.0001).

\textbf{Conclusion:} In present meta-analysis, the positive findings suggest rTMS has beneficial effects on PSD. However, those findings should be treated with caution because of heterogeneity and potential biases.
Practical tips around choosing pharmacotherapy

• Principles:
  – Evidence
  – Individual factors
    • Comorbidities
    • Drug-Disease Interactions
    • Drug-Drug Interactions
    • Past trials

– Older adults:
  • start slow, go slow (but go!)
  • Overall dose lower than younger adults
Practical tips around choosing pharmacotherapy

• SSRIs:
  – Least Drug-Disease and Drug-Drug Interaction with Escitalopram, Citalopram, and Sertraline
  – Higher drug-drug interactions with Paroxetine, Fluvoxamine, and Fluoxetine
  – ↑ QTc: Escitalopram and Citalopram (Max dose 10mg and 20mg respectively in older adults)

• SNRIs:
  – Venlafaxine: Dose adjustment may be needed with eGFR <30
  – Duloxetine: Avoid in severe renal impairment and chronic liver disease
Depression is common following stroke and associated with significant disability.

All stroke patients should be screened across the continuum of care.

There is limited evidence for psychotherapy in PSD at the present time.

Antidepressants are effective for PSD, and may also provide cognitive and functional benefit for individuals without depression.
Resources

• Geriatric Psychiatry Outreach Programs and Mood Disorder Program through Providence Care Hospital
• Canadian Coalition for Seniors Mental Health
  – www.cccsmh.ca
• Canadian Stroke Best Practices website (healthcare provider information and patient information):
  – www.strokebestpractices.ca, particularly:
• www.strokengine.ca
Taking Charge of Your Stroke Recovery
A SURVIVOR’S GUIDE TO THE CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS

BE INFORMED | BE INVOLVED | TAKE ACTION
Selected References/ Academic Resources

• Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015; International Journal of Stroke


Thank you

Maria Hussain MD FRCPC
Email: hussainm@providencecare.ca